U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV …
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · ABRYSVO is a bivalent vaccine that was designed to provide protection against RSV-LRTD, regardless of the virus subgroup. In the prefusion state, the RSV fusion protein …
GSK and Pfizer's RSV vaccines to carry warnings of neurological ...
2 days ago · Jan 7 (Reuters) - GSK , opens new tab and Pfizer's , opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing …
GSK, Pfizer RSV shots must warn about rare paralysis risk
1 day ago · Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. Photo by Beata Zawrzel/NurPhoto via …
FDA approves Pfizer's RSV vaccine for adults at increased risk of …
Oct 22, 2024 · The U.S. Food and Drug Administration on Tuesday approved Pfizer 's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 …
GSK, Pfizer RSV Shots to Warn About Rare Neurological Disorder
2 days ago · GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can …
FDA Approves Pfizer’s New RSV Vaccine for Older Adults
On May 31, the U.S. Food and Drug Administration (FDA) approved the second RSV vaccine in the world. The first, from the pharmaceutical company GSK, gained FDA approval earlier in …
FDA requires Pfizer, GSK to add warning on label of RSV shots
1 day ago · The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome …
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome ...
1 day ago · The RSV vaccine space is dominated by GSK and Pfizer, with the former being the undisputed leader. Arexvy was approved in May 2023 — one month ahead of Pfizer’s …
FDA Requires Guillain-Barré Syndrome (GBS) Warning
3 days ago · Abrysvo was initially approved on May 31, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 …